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Abstract
Interferons (IFNs) belong to the family of cytokines are widely used to treat 
keloids owing to their ability to increase collagenase activity thereby reducing the 
production of collagen and other extracellular matrix (ECM). Intralesional injec-
tion of IFN-α – 2b increases the collagenase level by inhibiting the secretion of 
metalloproteinases, an inhibitor of collagenase. Moreover, the anti-fibrotic activity 
of IFNs, interfere with fibroblast mediated collagen synthesis. On the other hand, 
combinatorial therapy has been preferred recently along with IFN due to its side 
effects observed in various clinical trials conducted only with IFN. Triamcinolone 
acetonide (TAC) and CO2 lasers along with IFNs are found to be the potential ther-
apy for the treatment of scars and keloids. In this chapter, IFN mediated therapy for 
the treatment of scars and keloids, its benefits and limitations and the advantages of 
combinatorial therapy with the appropriate literature support are discussed.
Keywords: hypertrophic scars, keloids, interferon, collagen synthesis,  
combinatorial therapy
1. Introduction
Hypertrophic scars and keloids are the most common skin disease associated 
with aesthetically disfiguring morphology, pain, itching, discomfort as well as psy-
chological stress and affect individual life style [1]. This disease is characterized by 
over production of extracellular matrix collagen and proteoglycans [2]. The devel-
opment of keloids involves unpredictable irregular arrangement of collagen and 
other extra cellular proteins in the milieu of wound healing. Wound healing is a well 
orchestrated sequential process happening through the four distinct steps such as 
hemostasis, inflammation, proliferation and tissue remodeling [3]. In hemostasis, 
immediately after an injury, platelet degranulation and activation of compliments 
initiates blood clotting and forms fibrin network at the site of injury which act as a 
scaffold for wound repair [4]. Platelet degranulation is crucial step for the release 
and activation of cytokines including epidermal growth factor (EGF), insulin like 
growth factor (IGF-I), platelet-derived growth factor (PDGF) and transforming 
growth factor β (TGF-β). These cytokines acts as chemotactic agents for the recruit-
ment of neutrophils, macrophages, epithelial cells, mast cells, endothelial cells 
and fibroblasts [5–7]. The recruited fibroblast, synthesis granulation tissue made 
up of procollagen, elastin, proteoglycans, hyaluronic acid and forms a structural 
repair framework to bridge the wound and allow vascular in growth. At that time, 
myofibroblast which contain actin filament initiates wound contraction. Once the 
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wound is closed, the abundant Extra Cellular Matrix (ECM) is then degraded and 
the immature type III collagen of the early wound is modified into mature type 
I collagen. Proper balance between ECM protein deposition and degradation is 
required for wound healing with minimal scarring. Once this balance is disrupted, 
abnormalities in scarring appear, resulting in the formation of either hypertrophic 
scar or keloids [8, 9]. The mechanism of Hypertrophic scar and keloid formation 
is given in the Figure 1. Both lesions are formed by the occurrence of imbalance 
between anabolic and catabolic process of wound healing, however keloids seems to 
be more aggressive fibrotic disorder compared to hypertrophic scars [10]. Keloids are 
more prevalent in Dark skinned individuals of Africa, Asia and Hispanic descents 
compared to Caucasians [11]. The occurrence of keloids in these population is 
found to be in the range of 5–16%. The risks of developing keloids are equal in both 
male and females. Due to the cosmetic procedures such as ear and nose piercing 
and physiological conditions like puberty and pregnancy, females have more risk 
for developing keloids compared to male. Persons with the age around 10 to 30 
are more prone to develop keloids compared to other age groups [12, 13]. Apart 
from sex and age, additional risk factor include having blood group A, hyper-IgE 
and hormonal peaks during pregnancy and puberty also play a role in developing 
keloids [14]. In recent days, numbers of gene and gene loci associated with keloid 
development have been identified. Single nucleotide polymorphism has identified 
in certain loci of NEDD4 genes by genome wide association studies and admixture 
mapping studies which is genetically linked to keloid development. In addition to 
that, several human leucocyte antigen (HLA) alleles, p53, bcl-2 and fas genes have 
also involved in keloid development [15–17]. Studies have also reported that people 
with rare genetic disorders including Dubowitz syndrome, Bethlem myopathy, 
Rubinstein-Taybi syndrome, Noonan syndrome and Geominne syndrome have the 
risk of developing keloids [15].
Figure 1. 
Mechanism of Hypertrophic scars and keloid formation.
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2. Currently available treatments
At present, various forms of treatment for keloids are available but no single 
therapeutic modality is best for all keloids. The size, location, depth of lesion, age, 
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response to the previous treatment determines the type of therapy need to cure 
keloids. Treatments including corticosteroids, surgical exsition, pressure therapy, 
radiotherapy, cryotherapy, laser therapy, 5- flurouracil, stem cell therapy, mitomy-
cin C application, Verapamil, Bleomycin, Botulinum toxin type A and ACE inhibi-
tors are available [18]. The current and emerging therapy for hypertrophic scars and 
keloids are briefly discussed in Table 1.
3. Interferons
In 1957, Isaacs and Lindeman identified a new substance which has the capacity 
to interfere with viral replication and coined the term “Interferon”. Interferons are 
the group of naturally occurring cytokines produced by the cells upon exposure to 
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various stimuli such as viruses, double – standard RNA and Polypeptides. Owing 
to its immunomodulatory, antiviral, antiangiogenic, anti-proliferative and antitu-
mor activities, interferons are used to treat various diseases including Hairy Cell 
Leukemia, Follicular Lymphoma, Renal cell carcinoma, melanoma, chronic hepatitis, 
AIDS-related Kaposi Sarcoma etc. In addition to their therapeutic properties, it is 
used to study the mechanism of mammalian signal transduction and transcriptional 
regulation.
4. Types of interferons
Currently, interferons are categorized in to four types namely alpha (α), beta 
(ß), gamma (ɣ) and Lambda (λ) interferon [62]. More recently, IFNs were divided 
into three major subgroups by virtue of their ability to bind to common receptor 
types namely type I, type II and type III. Type I IFNs bind to a type I IFN receptor 
and IFN-α, IFN-β belongs to type I IFN family. IFN-γ is the sole type II IFN, and 
binds to a distinct type II receptor. IFN-λ belongs to Type III IFN and binds to – 
IFNλR receptor [63–65]. Various types of IFN and their receptors and biological 
properties are given in the Table 2.
Alpha interferons are also called as ‘leukocyte interferon’ is a cytokine produced 
by innate immune system in response to external stimuli including viral infec-
tions [65–68]. Alpha interferons are categorized under type I interferons which 
processes antiviral, immunomodulatory as well as anti-proliferative properties. 
It was reported that at least 20 copies of genes which encodes alpha interferons in 
human genome and standard recombinant interferons alfa-2a, alfa-2b and alfa-con1 
(“consensus” interferon) have been produced [69].
Beta interferons (IFN β) are type I interferon produced by fibroblasts and  
possesses anti viral, anti proliferative and immunomodulatory effects. There are 
two forms of IFN β, IFN β- 1a and, IFN β- 1b both are used therapeutically. INF  
β -1b SC is produced by bacterial expression system and this was the first developed 
recombinant interferon for clinical use [63, 70].
Gamma interferon (IFN γ) is the only interferon categeroized under type II IFNs. 
IFN γ is produced by CD4T helper cell type 1 (Th1) lymphocytes, CD8 cytotoxic 
lymphocytes, NK cells, B cells and professional antigen-presenting cells (APCs). 
INF γ is acid liable where as other interferons are acid stable. IFN γ involved in 
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Table 2. 
Interferon Classification and properties.
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APS and lysosome activity of macrophages, activates inducible nitric oxide synthase 
(iNOS), induces the production of IgG2a and IgG3 from activated plasma B cells, 
Promotes adhesion and binding required for leukocyte migration [71–73].
Interferon lamda (IFN λ) was discovered in early 2003 and were categorized 
under type III interferon. There are three different interferon genes encodes and 
produce three different interferon λ proteins namely IFN λ1, INF λ2 and INF λ3. 
These proteins are also called as interleukin – 29 (IL-29), IL- 28 A and IL-28 B 
respectively [74]. IFN λ differ from other type I and type II interferon by signal-
ing mechanism. IFN λ, signals through heterodimeric acceptor complex. IFN λ is 
responsible for the development of anti tumor immune response and amplify the 
induction of antiviral activity of type I interferon. IFN λ processes anti viral activity 
and up regulate major histocompatibility complex (MHC) class I antigen expression 
on many cell types [75].
5. Interferon therapy for hypertrophic scars and keloids
Keloid is benign fibrous growth that extends outside the original wound and 
invades adjacent dermal tissue due to the excessive production of extra cellular 
matrix, especially collagen. Histologically, keloids are characterized by disorganized 
deposition of thick collagen fibers along with abundant lymphocytes, eosinophils 
and macrophages [76]. Although numerous attempts made to understand the 
pathophysiology and molecular abnormalities behind keloid formation, the exact 
pathogenesis of keloid formation is yet to be understood. Literature reports revealed 
that keloid shows an elevated expression of collagen mRNA, upregulation of TGF-β 
genes which results in excessive production of collagen and other ECM components 
especially fibronectin. TGF-β, especially the TGF-β1 isoform, is a key mediator of 
variety of processes including cell growth, proliferation, differentiation, apoptosis 
and responsible in many fibrotic diseases including keloids through its role in promot-
ing extracellular matrix (ECM) production and tissue fibrosis [77]. TGF-β belongs to 
the member of cytokine family which binds and activates dimerization of TGF-β type 
II receptors and the subsequent phosphorylation of TGF-β type I receptors, which 
phosphorylate and activate Smad2/3 leading to the translocation of Smad4 to the 
nucleus and activate the expression of target genes [78]. TGF-β receptors and Smad 
proteins are over expressed in keloids and hypertrophic scars compared to normal skin.
Matrix metalloproteinases (MMPs) or matrix metallopeptidases are calcium 
dependent zinc containing endopeptidases that plays a critical role in ECM forma-
tion. The major function of MMPs is to catabolize ECM and cleave regulate the 
activity of many other extracellular bioactive substrates [79]. MMPs are classified 
into 4 subsets namely collagenases, gelatinases, stromelysins, and membrane type. 
The collagenases including MMP-1, MMP-8, and MMP-13, cleave types I and III col-
lagens present in scar tissue. The activity of MMPs is regulated by tissue inhibitors 
of metalloproteinases (TIMPs) including TIMP-1, TIMP-2, TIMP-3, and TIMP-4, 
which inhibit MMPs. MMPs participate in inflammation, proliferation and remod-
eling phase of wound healing and MMPs involved in scars and keloid formation 
are also secreted by fibroblasts itself. An imbalance between MMP and TIMP leads 
to cause disturbance in collagen synthesis and degradation resulting in keloid and 
hypertrophic scar development [80–82].
Fibroblasts derived MT1-MMP and active MMP-2 play crucial roles in keloid for-
mation and tumor invasion. Excessive synthesis and deposition of collagen contrib-
ute to the development of keloids with prolonged and excessive presence of TGFβ-1. 
Downregulation of TIMP-2 leads to the progression of keloids because of relative 
increase of MT 1-MMP activity. MT 1-MMP increases the activity of TGFβ-1 lead to 
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collagen synthesis and collagen deposition in keloid development [83]. Schematic of 
keloid formation with respect to TGFβ-1 and MMP and role of interferon therapy in 
preventing TGFβ-1 and MMP mediated keloid development is given in the Figure 2.
Although many treatments and therapies are available for treating hypertrophic 
scars and keloids, the most efficient and successful treatment is yet to be achieved. 
Interferon therapy is one of the emerging therapies which have potential therapeu-
tic effect against keloids by decreasing the synthesis of collagen types I and III and 
increasing collagenase activity [84]. It has been reported that Interferon alpha and 
gamma decrease procollagen messenger RNA levels of fibroblasts both in normal 
and scleroderma patients and enhance collagenase activity. Interferon not only 
influences collagen synthesis in skin but also reduces the inflammatory reaction. 
Generally, Transforming Growth Factor (TGF) which is released by platelets at 
the site of injury is highly chemotactic to macrophages and monocytes during the 
inflammatory reaction. TGF also induces collagen and fibronectin production. 
Interferon antagonizing the effects of TGF-β and histamine there by reducing 
inflammatory reaction. Among the three isoforms of interferons, IFN-α and IFN-γ 
have been found to be very effective for keloid treatment since it decreases collagen 
and other ECM expression and increasing collagenase activity [85, 86].
Specifically, IFN - α2b is widely used in the treatment of keloids owing to its 
anti-proliferative property and reduce dermal fibrosis directly or antagonizing the 
effects of TGF-β and histamine. In addition, it was reported that IFN - α2b, increase 
collagenase levels and to inhibit the secretion of collagenase inhibitors such as 
metalloproteinases. Anti proliferative properties of IFN-α2b was demonstrated by 
Berman and Duncan. They have intralesionally injected 1.5 million IU IFN α-2b, 
twice over 4 days and found that size of the keloid was reduced to 50%. Post opera-
tive injection of IFN α-2b reduce the rate of recurrence to 19% as compared with 
that of intralesional steroid, where the rate of recurrence was 51% [87].
Injection of IFN into the suture line of keloid excision may be prophylactic 
for reducing recurrences. Post operative IFN- α2b injection treatment (5 million 
U, 1 million U injected per cm of scar) into keloid excision sites in 124 patients, 
fewer keloid recurrence rate (18%) was observed compared to excision site alone 
(51.1%) [88].
Figure 2. 
Mechanism of IFN therapy.
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Subcutaneous injection of human recombinant IFN- α2b (1x106 units) for 
7 days on a daily basis to patients with hypertrophic scars and then 2x106 units 
for 24 weeks in 3 times per week basis showed significant increase in the rate of 
scar improvement with control. Scar assessment and scar volume also improved 
after 3 months of treatment and no recurrences were observed after stopping IFN 
therapy.
Pittet et al. reported that intralesional injections of human recombinant IFN-γ 
200 mcg (6 X 106 U) per injection for 4 weeks to 7 patients with hypertrophic scar 
and observed that 7 of 7 patients showed decrease in redness, swelling, firmness, 
and lesion area. In addition to that, the reappearance of symptoms was minimal 
in only 2 of 7 patients and a small increase in the lesion area occurred in 4 of 
7 patients, although these lesions remained smaller than the original area was 
observed in 16th week [89].
IFN-γ play an important role in reducing fibrosis by inhibiting TGF-β via initial 
activation of Jak1, which in turn stimulates the negative regulator of collagen YB-1 
(Y-box protein-1), which activates Smad7, eventually leading to TGF-β1 suppres-
sion. Intralesional injection of IFN-γ has been shown to be effective in improving 
the appearance of keloids and hypertrophic scars, and also reducing keloid recur-
rence after excision along with variable treatment regimens [85].
6. Source and production of interferons
Commercially available interferons are human interferons manufactured 
by using recombinant DNA technology. There are many forms of interferons 
commercialized including interferon alfa-2a (Roferon-A), interferon alfa-2b 
(Intron-A), interferon alfa-n3 (Alferon-N), peginterferon alfa-2b (PegIntron, 
Sylatron), interferon beta-1a (Avonex), interferon beta-1b (Betaseron), inter-
feron beta-1b (Extavia), interferon gamma-1b (Actimmune), peginterferon 
alfa-2a (Pegasys ProClick), peginterferon alfa-2a and ribavirin (Peginterferon), 
peginterferon alfa-2b and ribavirin, (PegIntron/Rebetol Combo Pack), peginter-
feron beta-1a (Plegridy). Among these interferons, interferon alfa-2b (Intron-A) 
Figure 3. 
Structure of human recombinant interferon (a) INTRON® A (b) ACTIMMUNE®. (Reproduced from 
pubchem and EMBL-EBI respectively).
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and interferon gamma-1b (Actimmune) is used in the treatment of hypertrophic 
scars and keloids [90].
Interferon alfa-2b is commercialized under the trade name INTRON® A. It 
is a recombinant IFN available in the form of injection and molecular formula is 
C16H17Cl3I2N3NaO5S. The structure of this recombinant IFN is given in Figure 3. 
This IFN is water soluble proteins produced by recombinant DNA technology and 
possess molecular weight around 19000 Daltons. It is obtained from bacterial fer-
mentation of E.coli bearing genetically engineered plasmid containing an interferon 
alfa2b gene from human leukocytes. The specific activity of this recombinant IFN 
(INTRON® A) is approximately 2.6 x 108 IU/mg [91].
Interferon Gamma is commercialized under the trade name ACTIMMUNE®. 
It is a recombinant interferon produced by cloning of hIFNγ cDNA and expressed 
the recombinant in E.coli. Production and purification of recombinant IFNγ is cost 
effective. Molecular weight of the recombinant IFNγ in monomeric form is around 
17 kDa and dimeric form is around 35 kDa. The specific activity of this recombinant 
IFNγ is 3x106 IU/mg [92].
7. Combinatorial therapy
The most commonly employed treatment for keloid is Triamcinolone acetonide 
intralesional injection (TAIL). Major disadvantage of this therapy is limited success 
and adverse effects such as atrophy, telangiectasia, depigmentation, ulceration, and 
systemic effects, including cushingoid changes. In order to increase the success rate, 
TAIL is injected along with IFN – α 2 b. Twenty lesions (combined TAIL + IFN – α 2 
b group) and 20 control lesions (TAIL-only group) were studied in 19 patients. Both 
groups were treated with TAIL once in 2 weeks. The combined TAIL + IFN-alpha2b 
group was treated with intralesional injection of IFN – α 2 b, twice a week. Lesion  
measurements were noted. Statistically significant decreases in depth (81.6%, 
P = 0.005) and volume (86.6%, P = 0.002) were observed in lesions of the combined 
TAIL IFN – α 2 b group. In the TAIL-only group, the decreases in depth (66.0%, 
P = 0.281) and volume (73.4%, P = 0.245) were less statistically significant. Hence, 
injection of IFN – α 2 b enhances the healing potential of TAIL [93].
Combinatorial therapy of laser ablation in conjugation with IFN – α 2 b injec-
tion, showed better healing and reduction in recurrence rate towards keloid treat-
ment. 30 patients with keloids were chosen for the study. Among them, 16 patients 
have keloids on the ear and 14 patients on trunk. The duration of the study was 
12 to 24 months and the size of the keloids was ranged from 1 to 3 cm in diameter. 
Keloids were ablated using ultra pulse carbon dioxide laser followed by sublesional 
and perilesional injections of 3 million IU of IFN-α 2b three times per week. By this 
combinatorial therapy, the recurrence rate was reduced and observed that 66% of 
lesions did not recur after three years. In particular, no recurrence was observed in 
the auricular area [94].
Though IFN therapy is successful, treatment associated adverse effects including 
fever, headache, arthralgias, fatigue, chills, and confusion were observed and the 
treatment is expensive.
8. Summary and conclusion
Keloids are problematic disfiguring scars arises due to abnormal wound heal-
ing and excessive fibrosis. Un controlled proliferation of fibroblast results in over 
production and deposition of collagen and other ECM components responsible for 
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keloid development. There are many treatments available for hypertrophic scars 
and keloids including corticosteroid injections, surgical excision, pressure therapy, 
radiotherapy, laser therapy etc. Efficient and successful treatment for keloids is 
yet to be developed. Interferon therapy is one of the emerging therapies which 
have potential therapeutic effect against keloids by decreasing the synthesis of 
collagen types I and III and increasing collagenase activity. Recombinant IFN-α2b 
(INTRON® A) and IFN-γ (ACTIMMUNE®) is commercially available and used 
for the treatment of keloids. Significant improvement in rate of scar reduction 
and recurrence % was also decreased. In order to further improve the efficacy of 
IFN treatment, combinatorial therapy was attempted. IFN-α2b along with TAIL 
injection and CO2 laser ablation showed higher success rate. Hence, IFN and/or 
the combinatorial therapy would be a better treatment options to the patients with 
hypertrophic scars and keloids.
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